P

Pfizer

Biopharmaceutical company develops medicines and vaccines

Dedicated Care Coordinator - Mountain

Full-TimeUpdated on 10/1/2026Deadline 10/6/26
$162.9k - $271.5k/yr+ 20% bonus target + Share-based long-term incentive program
Expert
Bachelor's
Remote in USA+6 moreMore locations: North Dakota, USA | Wyoming, USA | Montana, USA | South Dakota, USA | Colorado, USA | Utah, USA
RemoteMust work in the Mountain Time Zone. Travel is approximately 10% to 20%.
No H1B Sponsorship

About the job

Requirements
  • A B.S. or B.A. degree and 8+ years of pharmaceutical or related experience in customer-facing roles or functions.
  • Experience as an FRM, PAC, ACM, FAS, or in access and reimbursement.
  • Demonstrated ability to communicate directly with patients, providers, and cross-functional colleagues.
  • Proficiency conducting benefit investigation and verification directly with payers, with working knowledge of prior authorization and appeals processes.
  • Working knowledge of copay programs, copay maximizers and accumulators, vouchers, and free or interim care programs.
  • Ability to own a high volume of concurrent cases across a patient journey averaging approximately 20 days, with disciplined documentation and follow-through.
  • Ability to meet adverse event reporting obligations in a role involving frequent, direct patient contact.
  • Strong understanding of reimbursement, government payment systems, specialty pharmacy networks, copay assistance programs, and specialty medications.
  • Ability to communicate and collaborate appropriately and compliantly with cross-functional field-based colleagues to ensure appropriate patient access.
  • Ability to align with headquarters stakeholders to support patient access.
  • Ability to work across different time zones if needed.
  • Permanent work authorization in the United States.
Responsibilities
  • Own 100% of assigned cases and drive the continual management and progression of the patient journey from HUB enrollment through post-fill follow-up.
  • Serve as the central point of contact for patients, caregivers, and healthcare providers regarding reimbursement and access support.
  • Answer patient and caregiver questions about access and coverage.
  • Maintain understanding of the patient access journey, requirements at each stage, and the roles of patients, caregivers, and healthcare providers.
  • Support access for healthcare providers and opted-in patients and caregivers prescribed a PDPA or VFM product.
  • Conduct Summary of Benefits discussions for HUB-enrolled patients, including product benefits, associated costs, and VFM baseline appointments.
  • Obtain missing information on Patient Enrollment Forms and verify testing, voucher, and Interim Care options selected by the healthcare provider’s office.
  • Explain out-of-pocket costs, deductibles, copay options, reimbursement programs, maximizers, and accumulators to patients.
  • Verify product and required baseline-test coverage across pharmacy benefit managers and major medical insurance for VFM.
  • Oversee prior authorization processes, including submission and verification with patients and providers.
  • Conduct benefit investigation and verification calls directly with payers and patients subject to third-party restrictions.
  • Confirm and communicate product coverage, costs, prior authorization and appeal requirements, Interim Care deadlines, and baseline assessment tests to healthcare providers and patients.
  • Schedule, reschedule, and confirm patient appointments with patients, providers, and vendors.
  • Secure confirmation communications from providers and coordinate patient assessment tests with IQVIA and MDX.
  • Manage Interim Care program administrative requirements and deadlines with providers and patients, including Extended Interim Care programs.
  • Confirm voucher need and eligibility and triage vouchers for shipment to patients.
  • Maintain copay portal access, help eligible commercial patients secure copay cards, and own copay eligibility attestations.
  • Follow up after prescription fill to confirm copay cards function correctly.
  • Triage vouchers, paid prescriptions, and Interim Care fills within Polaris.
  • Contact patients 10 days and 45 days after prescription to resolve logistical or financial questions.
  • Manage and update case types in Polaris using texting, faxing, and prescription-triage capabilities.
  • Review prior authorization, appeal, and Patient Enrollment Form documentation for accuracy.
  • Share and manage cases with HUB partners across patient journeys.
  • Coordinate with Pfizer colleagues and Patient Support Program or HUB employees through tasks and secure messages to resolve patient-case issues.
  • Maintain real-time case comments documenting the patient journey and every call with healthcare providers and patients.
  • Use Kiteworks encrypted email for correspondence with patients and providers.
  • Manage DocuSign processes to obtain required patient consents.
  • Report adverse events according to company requirements.
  • Operate within applicable content controls and system permissions.
  • Communicate access conditions and program options compliantly to patients, caregivers, and healthcare providers.
  • Link patient access support to patient needs using Brand Review Committee-approved materials.
  • Work cross-functionally with internal and external colleagues to improve the patient access journey.
  • Link customer insights to approved offerings and resources to address patient access barriers.
  • Build trust through compliant follow-up and knowledge of the access journey.
  • Communicate responsibly in written and spoken formats.
  • Travel approximately 10% to 20% as needed.
Desired Qualifications
  • Experience in a patient-facing or customer-facing role requiring access and reimbursement education.
  • Working proficiency in Polaris, including case management, documentation, prescription triage, and interpretation of prior authorization, appeal, and Patient Enrollment documents.
  • Experience working with a HUB.
  • Experience with Kiteworks or a comparable encrypted email platform, DocuSign, and copay portal administration.
  • Experience coordinating third-party vendors on patient assessment, testing, or specialty pharmacy logistics, including IQVIA, MDX, or Sonexus.
  • Experience supporting Interim Care, free-goods, or bridge programs.
  • Experience with pharmacy benefit manager and major medical benefit coverage pathways.
  • Excellent written and verbal communication skills.
  • Relationship-building skills, especially with older adults.
  • Trust, integrity, empathy, and patience in patient interactions.
  • Ability to deliver meaningful and concise presentations.
  • Strong attention to detail and organizational skills.
  • Critical-thinking skills and ability to understand complex processes and communicate them to diverse patient communities.
  • Collaboration and networking abilities.
  • Ability to work in a team environment.
  • Understanding of specialty pharmaceuticals and patient journeys.
  • Adherence to regulatory and compliance standards.

About the company

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $15.0 billion, and management raised full-year guidance to $60.5-$62.5 billion.
  • FDA approved Pfizer's 2026-2027 XFG Comirnaty vaccine on August 28, 2026.
  • Innovent and Metsera expand Pfizer's pipeline, while non-COVID revenue grew 5% operationally in Q2.

What critics are saying

  • Eliquis loses protection by 2028, and Ibrance faces U.S. patent expiry in 2027.
  • Pfizer just cut MET-224o and PF-07976016, proving obesity execution remains fragile versus Lilly.
  • Sanofi, Arbutus, and Bayer lawsuits target mRNA and LNP royalties, while restructuring runs through 2029.

What makes Pfizer unique

  • Pfizer spans vaccines, oncology, and cardiometabolic drugs across 2026, unlike narrower peers.
  • Metsera gave Pfizer monthly GLP-1 and amylin assets, plus obesity scale overnight.
  • Its global manufacturing and distribution network keeps Comirnaty, Padcev, and Vyndaqel commercially resilient.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -3%

1 year growth

↓ -3%

2 year growth

↓ -3%
Yahoo Finance
Sep 24th, 2026
Bristol Myers Squibb vs Pfizer: which healthcare stock is a better buy in 2026?

Bristol Myers Squibb and Pfizer, two pharmaceutical giants facing patent cliffs on blockbuster drugs, are taking divergent approaches to growth. Bristol Myers focuses on oncology and immunology whilst Pfizer leverages pandemic-era cash for acquisitions in high-growth areas like obesity treatments. Bristol Myers reported FY 2025 revenue of $48.2 billion, down 0.2% year-over-year, with net income of $7.1 billion and a 14.6% net margin. The company maintains a debt-to-equity ratio of 2.6x and generated $12.8 billion in free cash flow. Pfizer's FY 2025 revenue totalled $62.6 billion, declining 1.6%, with net income of $7.8 billion and a 12.4% net margin. Recent acquisitions include Seagen and Metsera, positioning the firm in oncology and obesity markets. Both companies partner with distributors and maintain global operations across multiple therapeutic areas.

Yahoo Finance
Sep 23rd, 2026
Pfizer and Butterfly Network lead AI healthcare push with revenues up to $63.7B

Butterfly Network is commercialising AI-enhanced ultrasound devices designed to assist clinicians with real-time scan guidance. The company generates approximately $112 million in revenue from its handheld iQ devices and related software platforms, including Compass AI and ScanLab, with a market capitalisation of roughly $2.2 billion. In November 2025, Butterfly's subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology. The deal includes a $15 million upfront payment, $10 million in annual licence fees, and additional milestone-based payments. Pfizer, with $63.7 billion in recent revenue and a market value of $158.1 billion, is applying biomolecular AI foundation models to accelerate drug discovery and development across its Global Biopharmaceuticals Business segment. The company combines large-scale therapeutic operations with machine learning applications in molecule design, trial productivity, and manufacturing efficiency.

Yahoo Finance
Sep 20th, 2026
Pfizer CEO says major headwinds easing as drugmaker cuts $7.2B in costs, eyes oncology pipeline

Pfizer's chief executive Albert Bourla says the pharmaceutical company's major headwinds are easing. Speaking at a recent conference, Bourla identified three challenges facing the drugmaker in 2025: tariffs and drug pricing policies, declining coronavirus product sales, and patent cliffs. The company has addressed tariffs by signing agreements with the US government for reduced medicine prices in exchange for tariff breaks. Pfizer has exceeded Wall Street's earnings-per-share estimates in all 10 of its past quarterly reports, suggesting its coronavirus business no longer significantly impacts performance. However, major patent cliffs loom. Eliquis, which generated $4.6 billion in the first half of the year, could face generic competition by 2028. Cancer treatment Ibrance, with $2.1 billion in first-half revenue, faces US patent expiration in 2027. Pfizer has cut $7.2 billion in costs and expanded its pipeline through acquisitions and internal development, with new products generating $13 billion annually. The company offers a 6.2% dividend yield.

Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.